Hepatitis B Patent Ruling 'Infected,' BMS Tells Fed. Circ.

Law360, New York (August 27, 2013, 6:12 PM EDT) -- Bristol-Myers Squibb Co. on Monday urged the Federal Circuit to reverse a decision that invalidated its patent covering the hepatitis B drug Baraclude, arguing that the district court relied on faulty legal reasoning to determine that the drug was obvious in favor of generic-drug maker Teva Pharmaceutical Industries Ltd.

In a 41-page brief, Bristol-Myers bashed the February decision by U.S. Magistrate Judge Christopher J. Burke, saying that the the court ignored multiple pieces of evidence that showed that Baraclude was a significant advance in an unpredictable...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.